Comparable stake leader
Behrenbruch Christian
SEC ownership of Telix Pharmaceuticals Ltd
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0002007191.
Disclosed value leader
Behrenbruch Christian
Comparable rows
45/46
Latest evidence
31 Mar 2026
- Public ticker
- TLX on Nasdaq, TLPPF on OTC
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Behrenbruch Christian
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
45 of 46
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Behrenbruch Christian
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0002007191
- Issuer location
- North Melbourne, Australia
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Telix Pharmaceuticals Ltd (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Behrenbruch Christian
Disclosed value leader
Behrenbruch Christian
Comparable rows
45/46
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 7%
1 rows are not safely comparable across share classes.
13D/G row: Behrenbruch Christian
Showing 1-8 of 46 holder rows.
Quick read
Behrenbruch Christian leads the comparable SEC ownership view at 7%.
45 of 46 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Behrenbruch Christian's linked filing trail.
Comparable ownership
Top 5
Behrenbruch Christian
7%
Kluge Andreas
6.8%
Mr. Mark Nelson
1.1%
Ms. Jann Skinner
0.18%
David Norman Cade
0.11%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 46 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Behrenbruch Christian |
13D/G
3/4/5
MD & Group CEO, Director
|
7%
|
$404,991,544
23,329,006 shares
|
$0 | 12 Nov 2024 |
| Kluge Andreas |
13D/G
|
6.8%
|
$393,638,000
22,675,000 shares
|
$0 | 12 Nov 2024 |
| Mr. Mark Nelson |
3/4/5
Director
|
1.1%
|
$27,179,337
3,628,750 shares
|
— | 18 Mar 2026 |
| Ms. Jann Skinner |
3/4/5
Director
|
0.18%
|
$4,474,400
595,000 shares
|
— | 18 Mar 2026 |
| David Norman Cade |
3/4/5
Group Chief Medical Officer
|
0.11%
|
$2,794,766
373,133 shares
|
— | 18 Mar 2026 |
| Darren Charlton Smith |
3/4/5
Group Chief Financial Officer
|
0%
|
$89,288
11,921 shares
|
— | 29 Mar 2026 |
| Ms. Marie McDonald |
3/4/5
Director
|
0%
|
$27,966
3,719 shares
|
— | 18 Mar 2026 |
| FMR LLC |
13F
Company
|
0.17%
|
$5,404,727
564,757 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$996,738.
Buys
$996,738
Insiders: 1
Sells
$0
Insiders: 0
Net
+$996,738
Shares: +67,935
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 67,935
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 67,935 | 0 | $996,738 | $0 | +$996,738 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to Telix Pharmaceuticals Ltd. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Behrenbruch Christian
Net 12M change
+$996,738
Latest report
11 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Behrenbruch Christian | MD & Group CEO, Director | $310,357,568 | +$996,738 | +0.32% | Mixed | 28 Apr 2026 |
| Mr. Mark Nelson | Director | $27,179,337 | Mixed | 18 Mar 2026 | ||
| Ms. Jann Skinner | Director | $4,474,400 | Mixed | 18 Mar 2026 | ||
| David Norman Cade | Group Chief Medical Officer | $2,794,766 | Mixed | 18 Mar 2026 | ||
| Darren Joel Patti | Group Chief Operating Officer | $191,429 | Mixed | 18 Mar 2026 | ||
| Darren Charlton Smith | Group Chief Financial Officer | $89,288 | Mixed | 29 Mar 2026 | ||
| Ms. Marie McDonald | Director | $27,966 | Mixed | 18 Mar 2026 | ||
| Maria Rivas | Director | Mixed | 11 May 2026 | |||
| William R. Jellison | Director | Mixed | 11 May 2026 | |||
| David N. Gill | Director | Mixed | 11 May 2026 |
Recent insider transactions for Telix Pharmaceuticals Ltd
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Christian Behrenbruch | TLX | Ordinary Shares | Purchase | 0.16% | $497,178 | $14.87 | 33,435 | 20,742,935 | 29 Apr 2026 | Elk River Holdings Pty Ltd |
| Christian Behrenbruch | TLX | Ordinary Shares | Purchase | 0.17% | $499,560 | $14.48 | 34,500 | 20,709,500 | 28 Apr 2026 | Elk River Holdings Pty Ltd |
| Darren Charlton Smith | TLX | Ordinary Shares | Options Exercise | 10.3% | 1,111 | 11,921 | 29 Mar 2026 | Direct | ||
| Darren Charlton Smith | TLX | Share Rights | Options Exercise | -100% | -1,111 | 0 | 29 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.